Coffee and caffeine dependence: What do we know now?

被引:0
作者
Nehlig, A [1 ]
机构
[1] Fac Med Strasbourg, INSERM, U398, F-67085 Strasbourg, France
来源
SEVENTEENTH INTERNATIONAL SCIENTIFIC COLLOQUIUM ON COFFEE, NAIROBI, JULY 20-25, 1997 | 1997年
关键词
D O I
暂无
中图分类号
S3 [农学(农艺学)];
学科分类号
0901 ;
摘要
Caffeine is the most widely used psychoactive substance in the world, Although it is usually consumed in rather modest amounts that induce mostly positive effects, caffeine has been considered incidentely as a drug of abuse or even a model of drug abuse. Therefore, the possibility that caffeine abuse, dependence and withdrawal should be added to diagnostic manuals has been considered in the United States. The present paper reviews the available data on caffeine dependence, reinforcement and withdrawal to try to assess in which respect caffeine differs from the classical drugs of abuse. After caffeine cessation, withdrawal symptoms develop in a large portion of the population but they are moderate and last only for a few days. Tolerance to the effects of caffeine on the central nervous system is very limited. Caffeine shows reinforcing properties but only at low doses while high doses induce dysphoric effects and are usually avoided. Conversely to the classical drugs of abuse which lead to quite specific increases in cerebral functional activity and dopamine release in the shell of the nucleus accumbens, the key structure for reward, motivation and addiction, caffeine does not primarily act at the level of that structure and increases glucose utilization in the shell of the nucleus accumbens only at rather high doses that stimulate most brain structures and are already somewhat aversive. In conclusion, although caffeine does share some features of dependence with classical drugs of abuse, they are not sufficient to consider that there is a strong dependence to caffeine in the general population.
引用
收藏
页码:35 / 42
页数:4
相关论文
共 50 条
  • [41] MENSTRUALLY RELATED DISORDERS - WHAT WE DO KNOW, WHAT WE ONLY BELIEVE THAT WE KNOW, AND WHAT WE KNOW THAT WE DO NOT KNOW
    HALBREICH, U
    CRITICAL REVIEWS IN NEUROBIOLOGY, 1995, 9 (2-3): : 163 - 175
  • [42] Hydrocephalus and mucopolysaccharidoses: what do we know and what do we not know?
    Dalla Corte, Amauri
    de Souza, Carolina F. M.
    Anes, Mauricio
    Giugliani, Roberto
    CHILDS NERVOUS SYSTEM, 2017, 33 (07) : 1073 - 1080
  • [43] Erratum to: What do we know? What do we need to know?
    Milena J. Henzlova
    W. Lane Duvall
    Journal of Nuclear Cardiology, 2017, 24 (1) : 255 - 255
  • [44] What Do We Know About the Safe Surgery Checklist Now?
    Haynes, Alex B.
    Berry, William R.
    Gawande, Atul A.
    ANNALS OF SURGERY, 2015, 261 (05) : 829 - 830
  • [45] TREATMENT WITH AN ULTRARAPID INHALED INSULIN - WHAT DO WE KNOW NOW?
    Boss, A. H.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2014, 16 : A12 - A13
  • [46] What do we know and what do we know about evolution?
    Vlchev, Boris
    SPISANIE NA B LGARSKOTO GEOLOGICHESKO DRUZHESTOV-REVIEW OF THE BULGARIAN GEOLOGICAL SOCIETY, 2020, 81 : 101 - 101
  • [47] Laparoscopic surgery and coronavirus disease: What do we know now?
    Ribeiro, Sergio Conti
    Lauletta, Ana Luisa F.
    Franco, Beatriz Couto
    Araujo Bezerra, Renata L.
    Salles Vanni, Diana G. B.
    Baracat, Edmund C.
    CLINICS, 2020, 75 : 1 - 3
  • [48] Presbyopia: What We Do Know and What We Do Not Know in 2022
    Grzybowski, Andrzej
    Gawecki, Maciej
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (03)
  • [49] Use of corticosteroids in the sepsis syndrome: What do we know now?
    LaRosa, SP
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2005, 72 (12) : 1121 - 1127
  • [50] Dialyzer reuse and patient outcomes: What do we know now?
    Robinson, BM
    Feldman, HI
    SEMINARS IN DIALYSIS, 2005, 18 (03) : 175 - 179